Etodolac XR
- Generic Name: etodolac extended release
- Brand Name: Etodolac XR
Etodolac XR(Etodolac Extended Release) side effects drug center
Etodolac XR Side Effects Center
Etodolac-XL Extended-Release is a nonsteroidal anti-inflammatory drug (NSAID) used to treat the symptoms of juvenile arthritis, rheumatoid arthritis, and osteoarthritis. Etodolac-XL is available in generic form. Common side effects of Etodolac-XL include:
- abdominal or stomach pain,
- constipation,
- diarrhea,
- gas,
- nausea,
- vomiting,
- indigestion,
- dizziness,
- weakness,
- headaches,
- high blood pressure,
- rash,
- itching,
- ringing in the ears,
- sore throat,
- runny nose, or
- flu symptoms
For relief of the signs and symptoms of osteoarthritis or rheumatoid arthritis, the recommended starting dose of etodolac extended-release is 400 to 1000 mg, given once daily. Dosage to treat juvenile arthritis is based on the child's body weight. Etodolac-XL may interact with ACE inhibitors, aspirin, furosemide and thiazides, lithium, methotrexate, and warfarin. Tell your doctor all medications and supplements you use. Use of etodolac-XL during pregnancy (particularly late pregnancy) should be avoided. It is unknown if etodolac-XL is excreted in breast milk. Consult your doctor before breastfeeding.
Our Etodolac-XL Extended-Release Tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Etodolac XR Professional Information
SIDE EFFECTS
A total of 1552 patients were exposed to etodolac extended-release tablets in controlled clinical studies of at least 4 weeks in length and using daily doses in the range of 400 to 1200 mg. In the tabulations below, adverse event rates are generally categorized based on the incidence of events in the first 30 days of treatment hwith etodolac extended-release tablets. As with other NSAIDs, the cumulative adverse event rates may increase significantly over time with extended therapy.
In patients taking NSAIDs, including etodolac extended-release tablets, the most frequently reported adverse experiences occurring in approximately 1-10% of patients are:
gastrointestinal experiences including: | ||
abdominal pain dyspepsia gross bleeding/perforation* |
constipation flatulence nausea |
diarrhea GI ulcers (gastric/duodenal)* vomiting |
other events including: | ||
abnormal renal function* dizziness headaches infection rashes |
anemia* edema* hypertension pharyngitis rhinitis |
asthenia elevated liver enzymes* increased bleeding time* pruritus tinnitus* |
* Adverse events that were observed in < 1% of patients in the first 30 days of treatment with etodolac extended-release tablets in clinical trials. |
Additional NSAID Adverse Experiences Reported Occasionally with NSAIDs or Etodolac Extended- Release Tablets Include:
Body as a whole – allergic reaction, anaphylactic/anaphylactoid reactions (including shock), chills, fever, sepsis
Cardiovascular system - congestive heart failure, flushing, palpitations, tachycardia, syncope, vasculitis (including necrotizing and allergic)
Digestive system - anorexia, cholestatic hepatitis, cholestatic jaundice, dry mouth, duodenitis, eructation, esophagitis, gastritis, gastric/peptic ulcers, glossitis, hepatic failure, hepatitis, hematemesis, intestinal ulceration, jaundice, liver necrosis, melena, pancreatitis, rectal bleeding, stomatitis
Hemic and lymphatic system - agranulocytosis, ecchymosis, eosinophilia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, purpura, thrombocytopenia
Metabolic and nutritional - hyperglycemia in previously controlled diabetic patients
Nervous system - anxiety, confusion, depression, dream abnormalities, insomnia, nervousness, paresthesia, somnolence, tremors, vertigo
Respiratory system - asthma, dyspnea, pulmonary infiltration with eosinophilia
Skin and appendages - angioedema, cutaneous vasculitis with purpura, erythema multiforme, hyperpigmentation, sweating, urticaria, vesiculobullous rash
Special senses - blurred vision, photophobia, transient visual disturbances
Urogenital system - dysuria, elevated BUN, oliguria/polyuria, proteinuria, renal failure, renal insufficiency, renal papillary necrosis, serum creatinine increase, urinary frequency
Other NSAID adverse reactions, which occur rarely are:
Body as a whole - anaphylactic reactions, appetite changes, death
Cardiovascular system - arrhythmia, cerebrovascular accident, hypotension, myocardial infarction
Digestive system - colitis, esophagitis with or without stricture or cardiospasm, thirst, ulcerative stomatitis
Hemic and lymphatic system - aplastic anemia, lymphadenopathy
Metabolic and nutritional - change in weight
Nervous system - coma, convulsions, hallucinations, meningitis
Respiratory - bronchitis, pneumonia, respiratory depression, sinusitis
Skin and appendages - alopecia, exfoliative dermatitis, maculopapular rash, photosensitivity, skin peeling, Stevens-Johnson syndrome, toxic epidermal necrosis
Special senses - conjunctivitis, deafness, hearing impairment, taste perversion
Urogenital System - cystitis, hematuria, interstitial nephritis, leukorrhea, renal calculus, uterine bleeding irregularities
Read the entire FDA prescribing information for Etodolac XR (Etodolac Extended Release)
&Copy; Etodolac XR Patient Information is supplied by Cerner Multum, Inc. and Etodolac XR Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.